Patient-Reported Outcomes With Adjuvant T-DM1 vs Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patient-Reported Outcomes From KATHERINE: A Phase 3 Study of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Cancer 2020 Apr 14;[EPub Ahead of Print], P Conte, A Schneeweiss, S Loibl, EP Mamounas, G von Minckwitz, MS Mano, M Untch, CS Huang, N Wolmark, P Rastogi, V D'Hondt, A Redondo, L Stamatovic, H Bonnefoi, H Castro-Salguero, HH Fischer, T Wahl, C Song, T Boulet, P Trask, CE GeyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.